Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Completed · Phase 3

Conditions studied: Asthma, Chronic Obstructive Pulmonary Disease (COPD)

In brief

This is a prospective, open-label, multicenter Phase 3 study evaluating the performance of the Albuterol Spiromax dose counter in patients with a diagnosis of asthma and/or COPD. The purpose of this study is to evaluate the functionality, reliability, and accuracy of the Albuterol Spiromax inhaler integrated dose counter in a clinical setting.

Key facts

Study ID

NCT01857323

Run by

Teva Branded Pharmaceutical Products R&D, Inc.

People needed

317

Starts

2013-05-01

Expected to finish

2013-09-01

Last updated by the study team

2015-06-08

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent/assent signed and dated by the patient and/or parent/legal guardian before conducting any study related procedure
• Male or female (non pregnant/non lactating) patients 4 years of age or older at the time of the screening visit (SV) who are able to understand English
• Females of childbearing potential (as judged by the investigator) currently using and will continue to use a medically reliable method of contraception for the entire study duration (e.g. oral, injectable, trans-cutaneous or implantable contraceptives or intrauterine devices or double-barrier protection). Females who are not sexually active must agree to use a medically reliable method of contraception should they become active during the course of the study. Women of childbearing potential, or less than 1 year postmenopausal, will require a negative urine pregnancy test at the SV. Female patients will be considered to be of non-child-bearing potential and will not require a urine pregnancy test if at least one of the following apply:a. before menarche; b. more than one year post-menopausal; c. had a hysterectomy, bilateral oophorectomy, salpingectomy, or tubal ligation; d. has congenital sterility
• General good health, defined as free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study
• Has a physician diagnosis of asthma or COPD with symptoms of bronchoconstriction requiring the use of short-acting β2-agonists
• Current Therapy: The patient's current asthma/COPD controller treatment regimen has remained stable for at least four weeks prior to the SV
• Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements (visits, record keeping, etc)
• Able to demonstrate satisfactory Spiromax inhaler use and technique.

You may not qualify if…

• History of life-threatening asthma or COPD that is defined for this protocol as an asthma or COPD episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures
• Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of the SV; or that occurs between the SV and TV1
• Is being treated with a long-acting β2-agonist alone
• Any asthma exacerbation requiring oral corticosteroids within 2 months of SV and any COPD exacerbation requiring oral corticosteroids within 1 month of the SV. A patient must not have been hospitalized for asthma or COPD within 4 months prior to the SV.
• Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular (e.g., congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease, cerebrovascular accident), hepatic, renal, hematological, neuropsychological, endocrine (e.g., uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), and/or gastrointestinal (e.g., poorly-controlled peptic ulcer or gastroesophageal reflux disease [GERD]). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the patient at risk through participation, or which could affect the endpoint analysis if the disease/condition exacerbated during the study.
• Uncontrolled hypertension (systolic blood pressure [BP] ≥160 mmHg or diastolic BP >100 mmHg)
• History of any adverse reaction, including immediate or delayed hypersensitivity to any β2-agonist, sympathomimetic drug, or any component of the Albuterol Spiromax DPI or rescue ProAir Hydrofluoroalkane (HFA) Metered-dose inhaler (MDI) formulation.
• Other exclusion criteria apply.

Where it is running

• Teva Investigational Site 10620 — Phoenix, Arizona, United States
• Teva Investigational Site 10637 — Costa Mesa, California, United States
• Teva Investigational Site 10635 — Huntington Beach, California, United States
• Teva Investigational Site 10647 — Rolling Hills Estates, California, United States
• Teva Investigational Site 10643 — San Diego, California, United States
• Teva Investigational Site 10644 — San Jose, California, United States
• Teva Investigational Site 10622 — Centennial, Colorado, United States
• Teva Investigational Site 10634 — Denver, Colorado, United States
• Teva Investigational Site 10645 — Wheat Ridge, Colorado, United States
• Teva Investigational Site 10633 — Miami, Florida, United States
• Teva Investigational Site 10640 — Ormond Beach, Florida, United States
• Teva Investigational Site 10641 — Overland Park, Kansas, United States
• Teva Investigational Site 10636 — Bethesda, Maryland, United States
• Teva Investigational Site 10631 — North Dartmouth, Massachusetts, United States
• Teva Investigational Site 10646 — Plymouth, Minnesota, United States
• Teva Investigational Site 10627 — St Louis, Missouri, United States
• Teva Investigational Site 10642 — Bozeman, Montana, United States
• Teva Investigational Site 10613 — High Point, North Carolina, United States
• Teva Investigational Site 10616 — Raleigh, North Carolina, United States
• Teva Investigational Site 10618 — Canton, Ohio, United States
• Teva Investigational Site 10615 — Oklahoma City, Oklahoma, United States
• Teva Investigational Site 10624 — Tulsa, Oklahoma, United States
• Teva Investigational Site 10625 — Eugene, Oregon, United States
• Teva Investigational Site 10626 — Medford, Oregon, United States
• Teva Investigational Site 10632 — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.